EP Patent

EP2213738A2 — siRNA molecules targeting Bcl-2

Assigned to Dharmacon Inc · Expires 2010-08-04 · 16y expired

What this patent protects

SiRNA molecules effective at silencing Bcl-2 are disclosed.

USPTO Abstract

SiRNA molecules effective at silencing Bcl-2 are disclosed.

Drugs covered by this patent

givosiran-sodium (GIVOSIRAN SODIUM)

Patent Metadata

Patent number: EP2213738A2
Jurisdiction: EP
Classification: —
Expires: 2010-08-04
Drug substance claim: No
Drug product claim: No
Assignee: Dharmacon Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.